Regulatory Compliance, Business Operations 16 Jan 2025 regulatory compliance, postal service, shipping contracts, negotiation agreements

📦USPS Notice on Priority Mail and USPS Ground Advantage Contract

The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a domestic shipping services contract to the list of Negotiated Service Agreements in the Mail Classification Schedule's Competitive Products List.

Learn More
Regulatory, Shipping Services 16 Jan 2025 regulatory compliance, postal service, negotiated service agreements, shipping, business logistics

📦Notice on USPS Priority Mail Express and Negotiated Agreement Changes

The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a domestic shipping services contract to the list of Negotiated Service Agreements in the Mail Classification Schedule's Competitive Products List.

Learn More
Regulatory Changes, Business Operations 16 Jan 2025 regulatory compliance, postal service, logistics, shipping, business contracts

📦USPS Notice

The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a domestic shipping services contract to the list of Negotiated Service Agreements in the Mail Classification Schedule's Competitive Products List.

Learn More
Compliance, Regulatory 16 Jan 2025 regulatory compliance, pharmaceuticals, fda, food safety, cosmetics, color additives, drugs

🚫FDA Revokes FD&C Red No. 3 for Food and Ingested Drugs

The Food and Drug Administration (FDA or we) is granting a color additive petition submitted by Center for Science in the Public Interest, et al., by repealing the color additive regulations that permit the use of FD&C Red No. 3 in foods (including dietary supplements) and in ingested drugs. The petitioners provided data demonstrating that this additive induces cancer in male rats. Therefore, FDA is revoking the authorized uses in food and ingested drugs of FD&C Red No. 3 in the color additive regulations.

Learn More
Regulatory Compliance, Financial Obligations 16 Jan 2025 regulatory compliance, securities exchange, financial implications, cat fee, industry members, miami international
Compliance, Regulatory Requirements 16 Jan 2025 regulatory compliance, virginia, nagpra, archaeology, cultural resources, human remains

⚖️Business Implications of Naval Weapons Station Disposition Notice

In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), Naval Weapons Station Yorktown (NWSY) intends to carry out the disposition of human remains removed from Federal or Tribal lands to the lineal descendants, Indian Tribe, or Native Hawaiian organization with priority for disposition in this notice.

Learn More
Regulatory Requirement, Business Implication 16 Jan 2025 regulatory compliance, postal service, shipping, e-commerce, business agreements

📦USPS Announces New Shipping Services Contract for 2025

The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a domestic shipping services contract to the list of Negotiated Service Agreements in the Mail Classification Schedule's Competitive Products List.

Learn More
Regulatory Compliance, Financial Impact 16 Jan 2025 regulatory compliance, postal service, shipping, usps, priority mail, business contracts

📦USPS Product Change for Priority Mail Express and Ground Advantage

The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a domestic shipping services contract to the list of Negotiated Service Agreements in the Mail Classification Schedule's Competitive Products List.

Learn More
Compliance, Regulatory, Energy 16 Jan 2025 regulatory compliance, energy, natural gas, filings, pipeline rates, u.s.
Regulatory Compliance, Industry Impact 16 Jan 2025 regulatory compliance, pharmaceuticals, fda, drug approval, new drug application, vanda pharmaceuticals

💊FDA Proposes Refusal of TRADIPITANT Drug Application

The Director of the Center for Drug Evaluation and Research (Center Director) at the Food and Drug Administration (FDA or Agency) is proposing to refuse to approve a new drug application (NDA) submitted by Vanda Pharmaceuticals, Inc. (Vanda), for TRADIPITANT capsules, 85 milligrams (mg), in its present form. This notice summarizes the grounds for the Center Director's proposal and offers Vanda an opportunity to request a hearing on the matter.

Learn More